Market Overview

Immunomedics Reports Advances With New Imaging Agent Developments for Positron Emission Tomography

Immunomedics, Inc. (Nasdaq: IMMU) today announced that 4 studies, using the Company's recently patented peptide labeling method with the radioisotope fluorine-18, for improved positron emission tomography imaging of diseases, were presented at the 2011 Annual Meeting of the Society of Nuclear Medicine.

The new labeling method involves the formation of an aluminum-18F complex, which is then bound to a NOTA ligand, attached to a peptide and is applicable to essentially any peptide that is stable at 100oC.

Posted-In: News FDA

 

Related Articles (IMMU)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional